VISTA and its ligands: the next generation of promising therapeutic targets in immunotherapy

被引：30

作者：

Shekari, Najibeh ^{[1
,2
]}

Shanehbandi, Dariush ^{[2
]}

Kazemi, Tohid ^{[3
]}

Zarredar, Habib ^{[4
]}

Baradaran, Behzad ^{[2
,3
]}

Jalali, Seyed Amir ^{[1
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran

[2] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran

[3] Tabriz Univ Med Sci, Dept Immunol, Sch Med, Tabriz, Iran

[4] Tabriz Univ Med Sci, TB & Lung Dis Res Ctr, Tabriz, Iran

来源：

CANCER CELL INTERNATIONAL | 2023年 / 23卷 / 01期

关键词：

VISTA; VSIG-3; PSGL-1; Immune checkpoint inhibitor; Immunotherapy; IMMUNE CHECKPOINT MOLECULE; SELECTIN GLYCOPROTEIN LIGAND-1; T-CELL; P-SELECTIN; CANCER-IMMUNOTHERAPY; IMMUNOGLOBULIN; PROTEIN; PSGL-1; BINDING; EXPRESSION;

D O I：

10.1186/s12935-023-03116-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V-domain immunoglobulin suppressor of T cell activation (VISTA) is a novel negative checkpoint receptor (NCR) primarily involved in maintaining immune tolerance. It has a role in the pathogenesis of autoimmune disorders and cancer and has shown promising results as a therapeutic target. However, there is still some ambiguity regarding the ligands of VISTA and their interactions with each other. While V-Set and Immunoglobulin domain containing 3 (VSIG-3) and P-selectin glycoprotein ligand-1(PSGL-1) have been extensively studied as ligands for VISTA, the others have received less attention. It seems that investigating VISTA ligands, reviewing their functions and roles, as well as outcomes related to their interactions, may allow an understanding of their full functionality and effects within the cell or the microenvironment. It could also help discover alternative approaches to target the VISTA pathway without causing related side effects. In this regard, we summarize current evidence about VISTA, its related ligands, their interactions and effects, as well as their preclinical and clinical targeting agents.

引用

页数：21